Ubs Group Ag Acadia Pharmaceuticals Inc Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Group Ag holds 455,551 shares of ACAD stock, worth $6.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

455,551

Previous 343,881 32.47%

Holding current value

$6.74 Million

Previous $6.36 Million 16.42%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$14.62 - $18.42 $1.63 Million - $2.06 Million	111,670 Added 32.47%	455,551 $7.4 Million
Q1 2024 May 13, 2024	BUY	$17.79 - $30.86 $649,726 - $1.13 Million	36,522 Added 11.88%	343,881 $6.36 Million
Q4 2023 Feb 09, 2024	BUY	$20.78 - $31.77 $3.38 Million - $5.17 Million	162,663 Added 112.42%	307,359 $9.62 Million
Q3 2023 Nov 09, 2023	BUY	$20.84 - $33.47 $104,095 - $167,182	4,995 Added 3.58%	144,696 $3.02 Million
Q2 2023 Aug 11, 2023	SELL	$17.8 - $25.65 $240,122 - $346,018	-13,490 Reduced 8.81%	139,701 $3.35 Million
Q1 2023 May 12, 2023	SELL	$16.32 - $20.92 $3.49 Million - $4.48 Million	-214,128 Reduced 58.29%	153,191 $2.88 Million
Q4 2022 Feb 08, 2023	BUY	$14.2 - $18.63 $4.49 Million - $5.89 Million	316,246 Added 619.2%	367,319 $5.85 Million
Q3 2022 Nov 10, 2022	BUY	$14.11 - $18.27 $243,693 - $315,541	17,271 Added 51.09%	51,073 $835,000
Q2 2022 Aug 10, 2022	SELL	$13.01 - $27.22 $385,499 - $806,555	-29,631 Reduced 46.71%	33,802 $477,000
Q1 2022 May 16, 2022	SELL	$20.94 - $27.5 $3.26 Million - $4.28 Million	-155,475 Reduced 71.02%	63,433 $1.54 Million
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $23,589 - $38,061	1,405 Added 0.65%	218,908 $5.11 Million
Q3 2021 Nov 15, 2021	BUY	$15.78 - $24.77 $3.25 Million - $5.09 Million	205,648 Added 1734.69%	217,503 $3.61 Million
Q2 2021 Aug 13, 2021	SELL	$19.4 - $27.42 $292,552 - $413,493	-15,080 Reduced 55.99%	11,855 $289,000
Q1 2021 May 12, 2021	SELL	$25.02 - $54.99 $293,384 - $644,812	-11,726 Reduced 30.33%	26,935 $695,000
Q4 2020 Feb 11, 2021	BUY	$41.04 - $56.79 $339,934 - $470,391	8,283 Added 27.27%	38,661 $2.07 Million
Q3 2020 Nov 12, 2020	BUY	$36.42 - $57.0 $216,735 - $339,207	5,951 Added 24.36%	30,378 $1.25 Million
Q2 2020 Jul 31, 2020	BUY	$39.26 - $52.73 $16,567 - $22,252	422 Added 1.76%	24,427 $1.18 Million
Q1 2020 May 01, 2020	SELL	$31.65 - $46.87 $3.66 Million - $5.42 Million	-115,667 Reduced 82.81%	24,005 $1.01 Million
Q4 2019 Feb 14, 2020	BUY	$36.21 - $51.4 $733,252 - $1.04 Million	20,250 Added 16.96%	139,672 $5.98 Million
Q3 2019 Nov 14, 2019	BUY	$22.22 - $44.01 $1.35 Million - $2.67 Million	60,565 Added 102.9%	119,422 $4.3 Million
Q2 2019 Aug 14, 2019	SELL	$23.32 - $28.12 $469,898 - $566,618	-20,150 Reduced 25.5%	58,857 $1.57 Million
Q1 2019 May 14, 2019	SELL	$16.17 - $27.38 $3.67 Million - $6.21 Million	-226,807 Reduced 74.17%	79,007 $2.12 Million
Q4 2018 Feb 14, 2019	SELL	$14.32 - $22.92 $55,275 - $88,471	-3,860 Reduced 1.25%	305,814 $4.95 Million
Q3 2018 Nov 14, 2018	BUY	$13.03 - $21.81 $1.72 Million - $2.88 Million	131,931 Added 74.23%	309,674 $6.43 Million
Q2 2018 Aug 14, 2018	SELL	$15.07 - $22.34 $3.94 Million - $5.84 Million	-261,344 Reduced 59.52%	177,743 $2.71 Million
Q1 2018 May 15, 2018	BUY	$22.47 - $32.33 $4.98 Million - $7.16 Million	221,465 Added 101.77%	439,087 $9.87 Million
Q4 2017 Feb 14, 2018	SELL	$26.84 - $39.14 $945,116 - $1.38 Million	-35,213 Reduced 13.93%	217,622 $6.55 Million
Q3 2017 Nov 14, 2017	BUY	$29.49 - $38.37 $234,592 - $305,233	7,955 Added 3.25%	252,835 $9.52 Million
Q2 2017 Aug 14, 2017	BUY	N/A	165,503 Added 208.5%	244,880 $6.83 Million
Q1 2017 Nov 14, 2017	BUY	N/A	79,377	79,377 $2.73 Million

Others Institutions Holding ACAD

# of Institutions

288

Shares Held

161M

Call Options Held

723K

Put Options Held

257K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.39B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account